Premium
Development and regulation of exosome‐based therapy products
Author(s) -
Batrakova Elena V.,
Kim Myung Soo
Publication year - 2016
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1395
Subject(s) - microvesicles , exosome , nanocarriers , drug delivery , ex vivo , computational biology , drug , nanotechnology , medicine , bioinformatics , in vivo , biology , pharmacology , microrna , microbiology and biotechnology , materials science , gene , biochemistry
Recently, various innovative therapies involving the ex vivo manipulation and subsequent reintroduction of exosome‐based therapeutics into humans have been developed and validated, although no exosome‐based therapeutics have yet to be brought into the clinic. Exosomes are nanosized vesicles secreted by many cells that utilize them for cell‐to‐cell communications to facilitate transport of proteins and genetic material. Comprised of cellular membranes with multiple adhesive proteins on their surface, exosomes offer distinct advantages that exceptionally position them as highly effective drug carriers. Additionally, exosomes can exert unique biological activity reflective of their origin that may be used for therapy of various diseases. In fact, exosomes have benefits of both synthetic nanocarriers and cell‐mediated drug delivery systems, and avoid their limitations. This concise review highlights the recent developments in exosome‐based drug delivery systems and the main regulatory considerations for using this type of therapeutic in clinic. WIREs Nanomed Nanobiotechnol 2016, 8:744–757. doi: 10.1002/wnan.1395 This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine